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Edited by Lukas HuberAbstract Lecithin cholesterol acyltransferase (LCAT) is a key
enzyme in the metabolism of high density lipoprotein (HDL),
which has been found inversely correlated with atherosclerosis.
Adenovirus mediated overexpression of human LCAT (hLCAT)
in hamsters resulted in increased levels of plasma total choles-
terol, HDL cholesterol, phospholipids and enlarged particle size
of HDL. It also increased cholesterol and total bile acid
concentrations in bile. Hepatic mRNA level of cholesterol 7a-
hydroxylase increased 2.7-fold in hamsters. However, such
eﬀects were not observed in mice in a parallel experiment. This
study suggests that overexpression of hLCAT in hamsters
facilitated reverse cholesterol transport. Similar metabolic
changes in humans might modify atherogenic risk.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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It is well established that reduced high density lipoprotein
cholesterol (HDL-C) is an independent risk factor for ath-
erosclerosis, a leading cause of cardiovascular disease and
death [1]. HDL intervention study also showed that an in-
crease of 1% in HDL-C is associated with a 3% reduction in
the risk of developing clinical atherosclerosis [2].
Lecithin cholesterol acyltransferase (LCAT) is a key enzyme
in cholesterol metabolism and has been hypothesized as a
potential therapeutic target for raising HDL-C and modulat-
ing atherosclerosis. In LCAT transgenic rabbits, HDL levels
were signiﬁcantly increased with reduced atherosclerotic le-
sions as expected [3,4]. However, studies using human LCAT
transgenic (hLCAT-Tg) [5–8] and LCAT-deﬁcient mice [9–11]
have yielded controversial results. Either enhanced [5] or un-
changed atherosclerosis [7,8] were documented in LCAT-Tg
mice. However, overexpression of hLCAT in chlolesteryl ester* Corresponding author. Fax: +86-10-82802769.
E-mail address: georgeliu@bjmu.edu.cn (G. Liu).
Abbreviations: CYP7, cholesterol 7a-hydroxylase; HDL, high density
lipoprotein; HMGR, 3-hydroxy-3-methylglutaryl-coenzyme A reduc-
tase; LCAT, lecithin cholesterol acyltransferase; RCT, reverse choles-
terol transport; TBA, total bile acid
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absent in this species, reduced diet-induced atherosclerosis
compared with LCAT-Tg mice [6]. It has also been shown that
LCAT knockout mice fed diﬀerent diet had either reduced
[9,11] or increased atherosclerosis [10] in LDLr)/) and apoE)/
) background, even though HDL levels were signiﬁcantly re-
duced in both situations.
On the other hand, lack of hepatic lipase (HL) and ApoAII
[12,13] in rabbits, both been important players in cholesterol
homeostasis, might aﬀect the direct extrapolation of the results
obtained in rabbits to humans. It is therefore necessary to ﬁnd
more appropriate models to address this issue further. In this
study, hamster was used for the ﬁrst time to assess the role of
hLCAT overexpression on plasma lipids, as well as on liver
lipids homeostasis and biliary cholesterol excretion. Adenovi-
rus mediated hLCAT overexpression in mice was performed in
a parallel experiment.
2. Materials and methods
2.1. Chemicals and reagents
The adenoviral vectors expressing human LCAT (Ad-hLCAT) and
human alkaline phosphatase (Ad-hAP) were generated according to
the application manual of AdEasy vector system (Qbiogene, CA,
USA). Mouse anti-hLCAT monoclonal antibody was a gift from
Kobori (Diagnostics Research Laboratories, Daiichi Pure Chemicals,
Japan). Other materials were purchased from following sources:
horseradish peroxidase-conjugated secondary antibody from Santa
Cruz (CA, USA); chemiluminescence regents, lecithin, human ApoA-I
from Sigma–Aldrich (MO, USA); [3H]cholesterol from Amersham
Biosciences (Buckinghamshire, UK).
2.2. Animal procedures
Three months old male golden Syrian hamsters or two months old
C57BL/6J male mice were housed and allowed free access to tap water
and commercial rodent diet. The ‘Principles of Laboratory Animal
Care’ (NIH Publication No. 85-23, revised 1996) were followed. Ani-
mals were anesthetized with pentobarbital sodium (45 mg/kg), and Ad-
hLCAT or control virus Ad-hAP at 1 1010 pfu in 0.5 ml PBS (for
hamsters) or 2 109 pfu in 0.2 ml PBS (for mice) was injected through
jugular vein under direct visualization. Six days after virus infection,
animals were anesthetized. Blood was taken from retro-orbital plexus
in overnight fasting animals. Hepatic bile was collected for 2 h via the
common bile duct cannulation with polyethylene tubing after cystic
duct was ligated (for mice, bile sample was drawn directly from the
gallbladder using an insulin syringe). Tissue samples were then har-
vested, snap-frozen in liquid N2 and stored at )80 C freezer.
2.3. RT-PCR and real-time RT-PCR
Total RNA was isolated from homogenized hamster tissues using
Trizol Reagent (Invitrogen, CA, USA). First-strand cDNA wasblished by Elsevier B.V. All rights reserved.
Fig. 1. The expression of hLCAT transgene in hamsters. (a) hLCAT
mRNA expression in hamster liver veriﬁed by RT-PCR. The size of
ampliﬁed fragments is 546 bp (for human LCAT) and 232 bp (for
hamster b-actin). Lanes 1–3: Ad-hAP treated hamsters; lanes 4–6: Ad-
hLCAT treated hamsters; lane M were 100 bp DNA ladder. (b) The
tissue expression pattern of human LCAT transgene determined by
real-time RT-PCR (n ¼ 4). The mRNA level of human LCAT was
presented as percent level relative to b-actin.
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RNA using RT kit (Invitrogen, CA, USA).
Quantitative real-time RT-PCR was performed using following
primer sets: hLCAT (50-GGATGTTTCCCTCTCGCATG-30; 50-GG-
GGATGCAGGGGGACCCTG-30); hamster b-actin (50-TCTGG-
CACCACACCTTCTAC-30; 50-AATGCCAGTGGTACGACC-30);
hamster 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR):
(50-CATGCAGCAAACATCGTCAC-30; 50-AGGATTGTCTTTG-
CA- CGCTC-30); hamster cholesterol 7a-hydroxylase (CYP7): (50-GG-
GATACTTCAAAGCCAGAC-30; 50-AGACGTATCAGTTCCGAG-
AC-30).
One microliter of the RT product and 1 SYBR green (Molecular
Probes, Eugene, USA) were included in the 25 ll reaction mixture (10
mM Tris–HCl, pH 8.3, 50 mM KCL, 1.5 mM MgCl2, 200 lM of
dNTP mix, 0.2 lM of each primer and 1 unit of TaqDNA polymerase)
for real-time RT-PCR. Thirty-ﬁve cycles of ampliﬁcation were per-
formed using an opticon continuous ﬂuorescence detection system (MJ
Research, MA, USA). Each cycle consisted of a 45-s denaturation at
94 C, a 45-s annealing at 56 C, and a 60-s extension at 72 C. The
mRNA levels were normalized to b-actin by using the comparative
cycle threshold (CT) method [14].
2.4. Western blot
Hamster plasma samples were subjected to electrophoresis on 12%
gels and transferred to nitrocellulose membranes (Sigma). After
blocking within 5% bovine serum albumin for 1 h, the membrane was
probed with 1 lg/ml mouse anti-human LCAT monoclonal antibody,
and followed by horseradish peroxidase-conjugated secondary anti-
body (goat anti-mouse, 1:2000). The reaction was detected by chemi-
luminescence and exposed to Kodak X-Omat ﬁlm (Kodak, Rochester,
USA).
2.5. Plasma LCAT activity and plasma lipids analysis
LCAT activity was determined by proteoliposome substrate as de-
scribed by Chen and Albers [15]. The substrate contained apoA-I,
[3H]cholesterol, and lecithin at a molar ratio of 0.8:12.5:250. The re-
action mixture containing 15 ll of plasma sample or 50 ll of culture
medium sample was incubated at 37 C for 30 min or 2 h, respectively.
Then the reaction was terminated by adding 1 ml of absolute ethanol.
Unesteriﬁed cholesterol and cholesteryl esters were separated using
thin-layer chromatography in petroleum ether/diethyl ether/acetic acid
(70:12:1, v/v) and the radioactivity was determined by scintillation
counting.
Plasma total cholesterol (TC) and triglyceride (TG) (Sigma kits), as
well as phospholipids (PL) (Wako kit, Osaka, Japan) were determined
by using enzymatic methods. Plasma HDL-C was measured after
precipitation of apoB-containing lipoproteins with an equal volume of
a 20% polyethylene glycol solution, as described by Liu et al. [16].
2.6. Non-denaturing gradient gel electrophoresis
Plasma HDL particle sizes were analyzed by non-denaturing gradi-
ent PAGE (polyacrylamide gel electrophoresis) as described by Rain-
water et al. [17]. A Hoefer SG gradient maker (Amersham Biosciences,
Buckinghamshire, UK) was employed to generate a 3–32% linear
gradient polyacrylamide gel. Plasma samples were prestained with 1%
Sudan black B in ethylene glycol (3:1, v/v) for 6 h, then mixed with 40%
sucrose (4:1, v/v), and 8 ll was applied to the gel. Electrophoresis was
carried out in a slab gel apparatus (Bio-Rad, USA) at 125 V constant
voltage at room temperature for 10 h in a buﬀer containing 90 mM
Tris, 80 mM boric acid, and 3 mM EDTA, pH 8.35.
2.7. Liver lipids analysis
Approximately 100 mg of liver (wet weight) was weighed and ho-
mogenized in 1 ml PBS. Lipids were extracted as described by Folch
et al. [18] and dissolved in 100 ll 3% Triton X-100. The determina-
tion of TC, TG and PL was carried out using enzymatic methods as
described above.
2.8. Bile analyses
Bile ﬂow was determined gravimetrically assuming a density of 1
g/ml. The total bile acid (TBA) concentration was measured using 3a-
hydroxysteroid dehydrogenase method [19]. Bile lipids were extracted
as described by Folch et al. [18] and dissolved in 3% Triton X-100. Ch
and PL were determined by similar kits.2.9. Statistical analysis
All data are presented as means S.E.M. Statistical comparison
between two groups was performed using Student’s t test. P < 0:05 was
considered statistically signiﬁcant.3. Results
3.1. Expression of hLCAT in hamsters and mice
Through pilot experiment, the viral dose of 1 1010 pfu/
100 g body weight and the day 6 after viral injection were
chosen for current study. The hLCAT mRNA was detected in
the liver of Ad-hLCAT infected hamsters by RT-PCR
(Fig. 1(a)). Majority of hLCAT mRNA (78.5%) was expressed
in the liver (Fig. 1(b)). A substantial level of hLCAT mRNA
were also expressed in lung (11.3%), spleen (4.4%) and heart
(3.5%). There was barely detectable level of the hLCAT
mRNA expression in kidney (1.8%) and testis (0.5%). By
Western blot, a molecular weight of 63-kDa protein, which is
consistent with the size of hLCAT, was detected in the plasma
of Ad-hLCAT infected hamsters (Fig. 2(a)). In contrast, this
band was absent in the control hamsters.
Plasma LCAT activity increased 10-fold in the hamsters
infected with Ad-hLCAT, as compared with the Ad-hAP
control (Fig. 2(b)). Mice infected with 2 109 pfu Ad-hLCAT
showed 23-fold increase of plasma LCAT activity, at a level
similar to that of hamster due to lower LCAT activity in
control mice (Fig. 2(b)).
Fig. 2. Mass and activity of hLCAT in the plasma. (a) Western blot
analysis of human LCAT protein in hamster plasma. Lane 1: serum
free culture medium of Ad-hLCAT infected Cos7 cells, which was used
as a positive control; lanes 2–4: Ad-hAP treated hamsters; lanes 5–7:
Ad-hLCAT treated hamsters. (b) Plasma LCAT activity in hamsters
(n ¼ 5 for each group) and mice (n ¼ 5 for each group). **P < 0:01.
Fig. 3. The analysis of HDL particle size in hamster plasma by non-
denaturing 3–32% gradient PAGE. Lane 1: human plasma used for a
comparison. Lanes 2 and 3: plasma samples from control hamsters.
Lanes 4 and 5: plasma samples from Ad-LCAT infected hamsters.
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Fig. 4. Liver lipids analysis. TC, TG and PL were analyzed in hamsters
(n ¼ 5 for each group) 6 days after infection with 1 1010 pfu Ad-
LCAT or Ad-AP. *P ¼ 0:01.
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A 10-fold increase of LCAT activity in hamsters resulted in
approximately 3.1-fold and 2.3-fold increase in plasma TC and
HDL-C levels, respectively, as compared with the control
(Table 1). Overexpression of hLCAT infection also resulted in
signiﬁcant increase of plasma PL levels in hamsters (P < 0:01).
In Ad-hLCAT infected mice, plasma TC increased 1.7-fold
(P < 0:01). HDL-C and PL were unchanged between the two
groups.
3.3. Alterations of HDL particle sizes in hamster plasma
The expression of hLCAT in hamster resulted in a major
alteration of plasma HDL size distribution (Fig. 3). An in-
cremental shift in HDL particle size in hamsters with hLCAT
overexpression was revealed by non-denaturing 3–32% gradi-
ent PAGE, compared to the control. The pattern of HDL size
distribution in control hamsters remained very similar to that
of human, which has been well characterized.
3.4. Alterations of lipids concentration in hamster liver
Since liver is the major organ responsible for the clearance of
excessive cholesterol in the body, we measured the lipids level
in the hamster liver (Fig. 4). There is no signiﬁcant diﬀerence inTable 1
Plasma lipids (mg/dl) in hamsters and mice infected with Ad-LCAT or Ad-A
TC TG
Hamster
Ad-hAP (n ¼ 5) 111.6 5.1 73.
Ad-hLCAT (n ¼ 5) 347.2 46.1a 47.
Mouse
Ad-hAP (n ¼ 5) 95.0 1.4 69.
Ad-hLCAT (n ¼ 5) 166.2 13.8b 51.
a P < 0:05, as compared with the Ad-hAP-infected control group.
b P < 0:01, as compared with the Ad-hAP-infected control group.TC and TG levels between Ad-hLCAT and Ad-hAP treated
hamsters. However, the PL levels in Ad-hLCAT treated
hamsters was slightly higher than that of control (157.7 4.4
vs 135.1 5.2 mg/g wet weight, P ¼ 0:01).
3.5. mRNA level of two related genes in the liver
Hepatic mRNA level of CYP7 in the Ad-hLCAT treated
hamsters increased about 2.7-fold compared to the control
(5.4 1.1% vs 2.0 0.4%, P < 0:05; Fig. 5). However, the he-
patic HMGR mRNA level in the Ad-hLCAT treated hamsters
decreased about 3.3-fold as compared with the control ham-
sters (1.5 0.3% vs 5.0 0.4%, P < 0:01).
3.6. Increased bile cholesterol excretion in hamster
There was no signiﬁcant diﬀerence in bile ﬂow between the
two groups of hamsters. However, 10-fold overexpression of
hLCAT in hamsters led to a signiﬁcant increase in bileP
PL HDL-C
0 8.8 199.3 4.0 53.9 3.8
7 2.2 289.7 18.8b 124.0 9.2b
6 5.9 275.9 5.6 60.4 1.5
2 7.7 286.0 11.8 71.3 5.7
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Fig. 5. Hepatic mRNA levels of HMGR and CYP7 in hamsters (n ¼ 5
for each group) determined by quantitative real-time RT-PCR. The
mRNA level was presented as percent level relative to b-actin.
*P < 0:05. **P < 0:01.
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Fig. 6. Bile cholesterol excretion during 2 h interval in hamsters (n ¼ 5
for each group). The value of total bile cholesterol excretion was cal-
culated as described in Section 2. *P < 0:05.
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28 A.-H. Zhang et al. / FEBS Letters 570 (2004) 25–29cholesterol and TBA as compared with the control (Table 2).
PL was not changed in Ad-hLCAT treated hamsters. Bile
cholesterol excretion, which was calculated by multiplying
total bile cholesterol concentration (Ch+TBA) with the bile
ﬂow during 2 h interval, increased signiﬁcantly as compared
with the control (3.99 0.53 vs 1.65 0.47 mg/100 body
weight, P < 0:05; Fig. 6). In Ad-hLCAT treated mice, the bile
cholesterol, TBA and PL concentrations remained unchanged
as compared with its control (Fig. 7).Fig. 7. Gallbladder bile lipids analysis in mice (n ¼ 5 for each group).
There was no signiﬁcant change in the concentration of gallbladder
bile cholesterol, PL, and TBA.4. Discussion
In the present study, we provided evidence that hamster,
which has both activities of CETP [20] and HL [21] in plasma,
is a better responder to hLCAT than mouse. Ten fold over-
expression of hLCAT in hamsters signiﬁcantly increased
plasma HDL-C and bile cholesterol excretion. However, such
eﬀects were not observed in mice in a parallel experiment.
Adenovirus-mediated gene transfer has been used to over-
express cholesterol metabolism related genes including apoAI
[22], LDLR [23], SR-BI [24] and CYP7 [25] in animals. Except
gutted adenovirus [26], transgene expression mediated by
commonly used adenoviral vectors in animals is stable for only
7–10 days, due to the development of immune response against
the recombinant adenovirus and transgenes [22–25]. Although
it is hard to directly evaluate the formation of atherosclerosis
by this method, information generated from above studies
proves to be valuable for establishing proof of principles and
for future research on atherosclerosis. In present study, we
therefore employed this method to explore the role of LCAT in
relation to reverse cholesterol transport (RCT), which may
further aﬀect atherosclerosis ultimately. Consistent with other
reports [22–25], hLCAT mRNA was preferentially expressedTable 2
Bile ﬂow and bile lipid analysis in hamster
Bile ﬂow (ll/min/100 g) Ch
Ad-hAP (n ¼ 5) 2.1 0.4 36.
Ad-hLCAT (n ¼ 5) 3.2 0.4 50.
a P < 0:05, as compared with the Ad-hAP-infected control group.
b P < 0:02, as compared with the Ad-hAP-infected control group.in the hamster livers. As noted, transient hepatic overexpres-
sion of hLCAT raised HDL-C levels, enlarged HDL particle
size and enhanced biliary cholesterol excretion. These results
implied enhanced RCT, a process that involves the removal of
cholesterol from peripheral cells to the liver for catabolism. We
therefore postulate that risk of atherosclerosis might be re-
duced if similar changes last for long time.
Theoretically, the increase of plasma HDL-C by hLCAT
overexpression would result in enhanced clearance of HDL
cholesteryl ester by the liver. However, such relationship has
not been explored yet by studies of LCAT overexpression [3–
8,27]. In the present study, we observed expression pattern of
two related genes in the liver that implied enhanced clearance
of HDL cholesteryl ester by the liver. HMGR and CYP7 are
the key enzymes involved in the endogenous cholesterol syn-
thesis and bile acid formation in the liver, respectively. The
decrease of HMGR mRNA level in hamster liver reﬂected
decrease of de novo cholesterol synthesis, which may result
from increased inﬂux of cholesterol into the liver. On the other
hand, the signiﬁcant increase of CYP7 mRNA level suggests(mg/dl) TBA (mg/dl) PL (mg/dl)
2 1.4 622.9 67.3 393.1 71.1
3 3.8a 960.8 51.3b 466.3 44.4
A.-H. Zhang et al. / FEBS Letters 570 (2004) 25–29 29an increase in the conversion of cholesterol into bile acid by the
liver. The later was conﬁrmed by the results of bile analysis.
Due to the inhibition of endogenous cholesterol synthesis and
increase of cholesterol clearance, hepatic cholesterol homeo-
stasis remained unchanged though plasma TC and HDL-C
increased signiﬁcantly. These results suggest that the whole
RCT was enhanced in hamsters with hLCAT overexpression.
In summary, this study demonstrated that transient hepatic
overexpression of human LCAT in hamster signiﬁcantly raised
the HDL cholesterol levels and increased bile cholesterol ex-
cretion, facilitating RCT, therefore supporting the antiather-
ogenic role of LCAT. With respect to HDL metabolism, the
hamster is certainly a better model for the study of hLCAT
overexpression than mouse.
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